RE: Issues on the Board8 Nov 2020 14:58
Tue, 2nd Jun 2020 11:29
RNS Number : 6974O
Hemogenyx Pharmaceuticals PLC
02 June 2020
On 14 May 2018, the Company announced a collaboration with GlobalCo to work on the Company's CDX antibody product candidate. Under the Agreement, which stipulates that GlobalCo's identity remain anonymous for the time being, the Company is receiving, free of charge, technical support, access to advanced methods of discovering, developing and engineering antibodies, and certain intellectual property necessary for the successful preclinical development of the Company's lead candidate bi-specific CDX antibody. This collaboration complements the Company's own development work that is currently being undertaken.
As a result of the global crisis caused by the COVID-19 pandemic, the Company and GlobalCo have agreed to extend the Agreement by three months in order to properly complete the work required by both parties thereunder.
The Company's CEO, Dr Vladislav Sandler, commented, "We are very pleased with the substantial work that has been done so far with our GlobalCo partner on our CDX antibody product candidate, and look forward to our continued collaboration and the successful completion of this important work."
Tue, 27th Oct 2020 07:00
RNS Number : 2594D
Hemogenyx Pharmaceuticals PLC
27 October 2020
On 14 May 2018, the Company announced a collaboration with GlobalCo to work on its CDX antibody. Under the Agreement, which stipulates that the GlobalCo's identity remain anonymous for the time being, Hemogenyx Pharmaceuticals receives - free of charge - technical support, access to advanced methods of discovering, developing and engineering antibodies, and certain intellectual property necessary for the successful preclinical development of the Company's lead candidate bi-specific CDX antibody. This work complements the Company's own development work currently being undertaken.
As a result of the global crisis caused by the COVID-19 pandemic, the Company has agreed with GlobalCo to a further extension of the Agreement until 31 December 2020 in order to properly complete the work required by both parties under the Agreement.
The Company's CEO, Dr Vladislav Sandler, commented, "We are pleased with the work that has been done so far on our CDX antibody product candidate with our GlobalCo partner, and look forward to our continued collaboration and completion of this significant work. This additional extension of the collaboration will allow us to choose the best CDX antibody for pre-clinical and clinical development."
between two rns only little add on is
"This additional extension of the collaboration will allow us to choose the best CDX antibody for pre-clinical and clinical development."
so it up to all of you to choose what to do with your money we will never sure this or that on time .
there are many project we need to hear some update but until now nothing yes like covid19 or at le